SAN DIEGO--(BUSINESS WIRE)--Apricus Biosciences (“Apricus Bio”) (Nasdaq: APRI), backed by a revenue generating CRO business and seeking to leverage its multi-route NexACT® drug delivery technology and internal pipeline through out-licensing partnerships, today provided a recap of its product pipeline development efforts, as presented by Bassam Damaj, Ph.D., President and Chief Executive Officer of Apricus Bio, at this afternoon’s PrecisionIR Informed Investors Forum Biotech, Healthcare and Pharma Virtual Conference. Details of the Company’s ongoing development efforts for NexACT and its pre-clinical and clinical product candidates include the following as of the date of this release:
